Stockscreener 앱 받기
2.99
4.78%
-0.15
Eyepoint Inc 주식(EYPT)의 최신 뉴스
Here's Why You Should Add EYPT Stock to Your Portfolio Now - Zacks Investment Research
Five parties report an EyePoint (EYPT) stake but disclaim ownership of shares held by Managed Funds. - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - GlobeNewswire Inc.
PV3B Stock Price and Chart — HAN:PV3B - TradingView
PV3B Stock Price and Chart — HAN:PV3B - TradingView
EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - kalkine.ca
EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - kalkine.com.au
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against EyePoint, Inc. (EYPT) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT) - The Globe and Mail
EYPT Investigation Alert: EyePoint, Inc. Investors Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
EyePoint at Cantor conference: mixed trial data leaves key catalyst ahead - Investing.com Canada
EyePoint at Cantor conference: mixed trial data leaves key catalyst ahead - Investing.com India
EyePoint posts updated presentation showing LUGANO Phase 3 DURAVYU topline results, NDA path to H1 2027 - TradingView
Eye drug cuts injections 42% in EyePoint (EYPT) trial but misses its main goal - Stock Titan
EyePoint Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Transcript : EyePoint, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
EyePoint at Citi summit: wet AMD setback, but path stays open - Investing.com India
EyePoint at Citi summit: wet AMD setback, but path stays open - Investing.com Nigeria
EyePoint at Citi summit: wet AMD setback, but path stays open - Investing.com UK
EyePoint at Citi summit: wet AMD setback, but path stays open By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - GlobeNewswire Inc.
INVESTIGATION ALERT: Investigation Launched Into EyePoint, Inc. (EYPT), Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - Barchart.com
Investment firm discloses double-digit stake in EyePoint (EYPT) - Stock Titan
EyePoint's stock plunges 66% after failed Phase 3 trial for wet AMD treatment. - Pluang
Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - PR Newswire
EYPT News | EYEPOINT INC (NASDAQ:EYPT) - ChartMill
EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm - GlobeNewswire Inc.
EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO - finance.yahoo.com
EyePoint faces securities fraud probe after tri... - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - PR Newswire
EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals - GlobeNewswire
EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
EyePoint stock drops as TD Cowen downgrades (EYPT:NASDAQ) - Seeking Alpha
TD Cowen Downgrades EyePoint Pharmaceuticals to Hold From Buy, Adjusts PT to $4 From $20 - marketscreener.com
EyePoint Announces Upcoming Investor Conference and Retina Society Presentations - quiverquant.com
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting - marketscreener.com
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting - GlobeNewswire
TD Cowen downgrades EyePoint stock to Hold on trial concerns By Investing.com - Investing.com Canada
TD Cowen downgrades EyePoint stock to Hold on trial concerns - investing.com
TD Cowen downgrades EyePoint stock to Hold on trial concerns By Investing.com - Investing.com UK
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm - Sahm
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law - financialcontent.com
Eyepoint Pharmaceuticals Inc (EYPT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law - Business Wire
Eyepoint Pharmaceuticals Inc (EYPT) Peer Comparison – Compare with Others - Value Research
EyePoint After LUGANO: Primary Endpoint Miss, Asymmetric Risk-Reward (NASDAQ:EYPT) - Seeking Alpha
4.22%
자본화:
|
볼륨(24시간):